{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:38:54Z","timestamp":1754397534086},"reference-count":39,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1507\/endocrj.k07e-055","type":"journal-article","created":{"date-parts":[[2008,5,12]],"date-time":"2008-05-12T05:50:25Z","timestamp":1210571425000},"page":"351-357","source":"Crossref","is-referenced-by-count":5,"title":["Sustained Clinical Inactivity and Stabilization of GH\/IGF-1 Levels in an Acromegalic Patient after Discontinuation of Somatostatin Analogue Treatment"],"prefix":"10.1507","volume":"55","author":[{"given":"Avraam","family":"AVRAMIDIS","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hippokratio General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stergios A.","family":"POLYZOS","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hippokratio General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"EFSTATHIADOU","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hippokratio General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"KITA","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hippokratio General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2646"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90: 1377-1382.","DOI":"10.1210\/jc.2004-1974"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67: 65-70.","DOI":"10.1111\/j.1365-2265.2007.02836.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153: 737-740.","DOI":"10.1530\/eje.1.02036"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Duncan E, Wass JA (1999) Investigation protocol: acromegaly and its investigation. Clin Endocrinol (Oxf) 50: 285-293.","DOI":"10.1046\/j.1365-2265.1999.00615.x"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.9.3034"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2004) Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and\/or radiotherapy. Clin Endocrinol (Oxf) 60: 375-381.","DOI":"10.1111\/j.1365-2265.2004.01992.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66: 859-868.","DOI":"10.1111\/j.1365-2265.2007.02825.x"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.9.2768"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Vance ML, Harris AG (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 151: 1573-1578.","DOI":"10.1001\/archinte.1991.00400080073013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chanson P (2000) Somatostatin analogs in the treatment of acromegaly: the choice is now possible. Eur J Endocrinol 143: 573-575.","DOI":"10.1530\/eje.0.1430573"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83: 249-257.","DOI":"10.1159\/000095535"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical `cure'. Eur J Endocrinol 152: 379-387.","DOI":"10.1530\/eje.1.01863"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.53.125"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355: 2558-2573.","DOI":"10.1056\/NEJMra062453"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90: 1856-1863.","DOI":"10.1210\/jc.2004-1093"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2110"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-011841"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59: 115-128.","DOI":"10.1046\/j.1365-2265.2003.01811.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumor shrinkage with dissociation between anti-proliferative and anti-secretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92: 1592-1599.","DOI":"10.1210\/jc.2006-2084"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.7.2976"},{"key":"22","unstructured":"22. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW (1992) Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 131: 571-577."},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.227"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shimon I, Melmed S (1998) Management of pituitary tumors. Ann Intern Med 129: 472-483.","DOI":"10.7326\/0003-4819-129-6-199809150-00009"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jaffe CA, Barkan AL (1992) Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21: 713-735.","DOI":"10.1016\/S0889-8529(18)30210-X"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61: 209-215.","DOI":"10.1111\/j.1365-2265.2004.02082.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Abs R, Verhelst J, Maiter D, Van AK, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83: 374-378.","DOI":"10.1210\/jcem.83.2.4556"},{"key":"28","unstructured":"28. Plockinger U, Liehr RM, Quabbe HJ (1993) Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone\/insulin-like growth factor-I concentrations and on serum gastrin\/24-hour intragastric pH values. J Clin Endocrinol Metab 77: 157-162."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lorcy Y, Dejager S, Chanson P (2000) Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 3: 193-197.","DOI":"10.1023\/A:1011416112730"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Caron P, Tabarin A, Cogne M, Chanson P, Jaquet P (2000) Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients: clinical implications. Eur J Endocrinol 142: 565-571.","DOI":"10.1530\/eje.0.1420565"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117: 711-718.","DOI":"10.7326\/0003-4819-117-9-711"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Livadas S, Hadjidakis DJ, Argyropoulou MI, Stamatelatou M, Kelekis D, Raptis SA (2006) Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens) 5: 57-63.","DOI":"10.14310\/horm.2002.11169"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Colao A, Pivonello R, Rosato F, Tita P, De ME, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 64: 342-351.","DOI":"10.1111\/j.1365-2265.2006.02467.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764-772.","DOI":"10.1210\/jcem-60-4-764"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Wang C, Lam KS, Ma JT, Chan T, Liu MY, Yeung RT (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27: 363-371.","DOI":"10.1111\/j.1365-2265.1987.tb01163.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179-1183.","DOI":"10.1210\/jcem-58-6-1179"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Esiri MM, Bevan JS, Burke CW, Adams CB (1986) Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 63: 383-388.","DOI":"10.1210\/jcem-63-2-383"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Gutt B, Hatzack C, Morrison K, Pollinger B, Schopohl J (2001) Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly. Eur J Endocrinol 144: 109-116.","DOI":"10.1530\/eje.0.1440109"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91: 1239-1245.","DOI":"10.1210\/jc.2005-1616"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/55\/2\/55_K07E-055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:47:07Z","timestamp":1618296427000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/55\/2\/55_K07E-055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k07e-055","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}